Does aspirin raise the risk of age-related eye disease?
Genetic evidence linked aspirin use to higher risk of early and dry forms of age-related macular degeneration.
This eye disease can harm sharp, central sight. The 2026 study in *Eye* used genetic data to explore the link. It did not assign people to take aspirin. Instead, researchers used inherited genetic differences as clues to possible cause and effect. The source summary does not give the number or ages of people studied.
For this community, the key finding involves ApoA1, a protein that helps carry fats in blood. Aspirin use was linked to higher ApoA1 and lower LDL Cholesterol. Both changes appeared to explain the link with early and dry eye disease.
After accounting for these blood markers, researchers found no clear remaining direct effect of aspirin. Their analysis suggested that the link worked through these blood fat changes. That is not proof that a higher ApoA1 result predicts eye disease. The summary gives no risk percentage or size of the blood-level changes. It also does not state the aspirin dose. That leaves questions for members tracking Low Dose Aspirin.
For members uploading bloodwork, this adds context rather than a new target number. ApoA1 trends can sit alongside other blood results and medication records. Comparing dated results with community peers may help build a fuller picture. But those shared patterns cannot show whether aspirin caused a change. This study also does not tell us what any one person's result means for their sight.
What patterns have you noticed in your ApoA1 results alongside your medication history?

Comments
No comments yet.